Pure Global AI
NCT06266715Recruiting

Improvement of Depression With Use of ATP

A Double-blind Randomized Controlled Trial of Adenosine Disodium Triphosphate in Improving Moderate to Severe Depressions
Nanfang Hospital, Southern Medical UniversityClinicalTrials.govdrug
Verified
Study focus
Disease/Condition
Depression
Drug/Device/Intervention
ATP Group
Study type
Interventional
Intervention type
drug
Sponsor & location
Primary sponsor
Nanfang Hospital, Southern Medical University
Location
Guangzhou, China
Timeline & enrollment
Phase
N/A
Start date
Mar 04, 2024
End date
Dec 31, 2026
Enrollment
120 participants
Primary outcome

HAMD-24

Summary

This clinical study is a randomized, double-blind, placebo-controlled trial with an
 intervention period of 4 weeks. Participants will be patients with moderate to severe
 depression who meet the inclusion criteria during the screening period. After recruitment
 written informed consent form will be signed and the baseline evaluation will be done then
 the treatment period follows. The subjects will be randomly assigned to a control group
 (escitalopram plus normal saline(NA)) and an ATP group (escitalopram plus adenosine disodium
 triphosphate(ATP)) in a 1:1 ratio for treatment, with a total number of 120 recruited
 patients. Assessment will be carried out as an analysis of changes in Hamilton Depression
 Scale（HAMD-24）, cognitive function test, brain functional network, inflammatory markers, and
 other indicators in the first, second, and fourth week of intervention which will evaluate
 the effectiveness of ATP in improving moderate to severe depression preliminarily.

ICD-10 classifications
Depressive episodeOther depressive episodesRecurrent depressive disorderRecurrent depressive disorder, unspecifiedPost-schizophrenic depression
Data source
Registry
ClinicalTrials.gov
Trial ID
NCT06266715
Type
Non-Device Trial
About this record

Access comprehensive clinical trial information for NCT06266715 through Pure Global AI's free database. This phase not specified trial is sponsored by Nanfang Hospital, Southern Medical University and is currently Recruiting. The study focuses on Depression. Target enrollment is 120 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.